Abstract | BACKGROUND:
Macular edema (ME) treatment has benefited from the recent intravitreal pharmacotherapy development of an intravitreal implant of dexamethasone (Ozurdex(®), Allergan, Irvine, Calif., USA). However, its efficiency has never been illustrated beyond 3 injections. CASE PRESENTATION: CONCLUSIONS: This case report highlights the quick efficiency of Ozurdex on VA and ME with good reproducibility and tolerance, and without tachyphylaxis phenomenon. This is the first illustrated description of 4 consecutive injections for ME induced secondary to retinal vein occlusion.
|
Authors | Frederic Matonti, Louis Hoffart, Christophe Baeteman, Danièle Denis |
Journal | Case reports in ophthalmology
(Case Rep Ophthalmol)
Vol. 3
Issue 3
Pg. 339-42
(Sep 2012)
ISSN: 1663-2699 [Electronic] Switzerland |
PMID | 23139679
(Publication Type: Case Reports)
|